RCT on Red Light Treatment for Myopic Minors' Retinal Impact

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06034912
Collaborator
(none)
70
1
11.1
6.3

Study Details

Study Description

Brief Summary

  1. Research Objective: The primary objective is to investigate the short-term effects of repetitive low-intensity red light therapy on the fundus of the eyes of underage individuals with myopia.

  2. Research Design: This experiment employs a prospective, single-center, randomized, controlled clinical research design.

  3. Primary Outcome: Changes in macular sensitivity (microperimetry).

  4. Recruitment and Participant Information: The study population consists of individuals aged 7 to 17 years old. It is anticipated that there will be 35 participants in both the control group and the experimental group.

  5. Trial Location: Zhongshan Ophthalmic Center, Sun Yat-sen University. Contact Information: Shuyu Chen, +190805155537, chenshuyu980916@163.com.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    1. Research Design: This study is an observational research aimed at investigating the short-term effects of repeated low-intensity red light therapy on the fundus of underage individuals with myopia. Retinal light damage typically occurs in the photoreceptor layer and retinal pigment epithelium. Optical coherence tomography angiography (OCTA), OCT, pattern visual evoked potentials (VEP), microperimetry, and multifocal electroretinography (ERG) will be utilized to assess the functionality of the retina, choroid, and optic nerve, thus identifying potential areas of damage. This will provide a scientific basis for further evaluating the safety of low-intensity red light therapy.

    2. Participant Recruitment:

    (1) Age range: 7 to 17 years old. (2) Spherical equivalent refraction (SER): -1.00 to -5.00D. (3) Astigmatism: ≤ 2.50D. (4) Refractive anisometry (difference between the two equivalent spherical lenses): ≤ 1.50D.

    (5) Best corrected visual acuity (BCVA) in either eye: ≥ 20/20. (6) Willingness to undergo low-intensity red light treatment. (7) Ability to comprehend the trial's purpose, voluntary participation, and signing of an informed consent form by the subject and their legal guardian.

    3.Intervention:Control Group: Daily wear of frame glasses for refractive correction, without any additional treatment for myopia control.Experimental Group: Daily wear of frame glasses for refractive correction, along with low-intensity red light therapy as prescribed by the optometrist.

    4.Data Collection: All examinations are conducted by experienced doctors,technicians, and optometrists during objective assessments. Data collection forms are incorporated into the medical records. Specialized research coordinators conduct regular follow-up with all subjects via telephone or WeChat.

    5.Ethical Review: The trial protocol was developed before the clinical trial commenced and received approval from the ethics committee.

    6.Results and Analysis: Data statistical analysis will be performed using SPSS 26.0 statistical software. The Kolmogorov-Smirnov test will be employed for normality distribution testing. Variables following a normal distribution will be expressed as mean ± standard deviation (Mean±SD). Between-group comparisons will be conducted using one-way analysis of variance. Paired t-tests will be used for pre- and post-red light exposure data. Non-normally distributed data will be expressed as median (interquartile range) [M(Q)] and analyzed using rank-sum tests. A significance level of P < 0.05 will indicate statistically significant differences.

    7.Safety and Side Effects: None. 8.Discussion and Conclusion: None.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    70 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Randomized Controlled Study on the Effects of Repetitive Low-Intensity Red Light Therapy on the Retina of Minors With Myopia
    Actual Study Start Date :
    Jun 28, 2023
    Anticipated Primary Completion Date :
    Mar 29, 2024
    Anticipated Study Completion Date :
    May 31, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    experimental group

    Intervention method:Wearing frame glasses daily + low-intensity red light irradiation for myopia treatment. Planned visits and durations: Follow-up visits will be conducted with patients before red light irradiation, on the first day after two sessions of red light irradiation, before red light irradiation on the second day, one month later, three months later, and six months later.

    control group

    Intervention method::Wearing frame glasses daily Planned visits and durations:After participating in the study, follow-up will be conducted six months later."

    Outcome Measures

    Primary Outcome Measures

    1. Changes in visual acuity in the macula (micro-visual field) [1 day、1 month、3 months、6 monthes after treatment]

      All participants were treated with a microvisual field meter for fundus imaging and microvisual field examination without mydriasis.

    Secondary Outcome Measures

    1. Amplitude and latency of P100 waves [1 day、1 month、3 months、6 monthes after treatment]

      Pattern visual evoked potentials (P-VEP) were used to detect the functional integrity of the visual pathway, and the amplitude and latency of the P100 wave were recorded.

    2. Choroidal thickness [1 day、1 month、3 months、6 monthes after treatment]

      Optical coherence tomography (OCT) was used for choroidal thickness measurement.

    3. Amplitude and latency of P1 waves [1 day、1 month、3 months、6 monthes after treatment]

      Multifocal electroretinaogram (mfERG) was used to detect the electrophysiological activity of the local retina of the macula, and the amplitude of P1 wave (expressed by reaction density) and latency were recorded.

    4. Choroidal and retinal blood flow density assessment [1 day、1 month、3 months、6 monthes after treatment]

      Optical coherence tomography angiography (OCTA) was used to scan the choroidal and retinal scans of both eyes to check the blood flow density of the choroidal capillary layer, superficial retinal capillary layer, middle retinal capillary layer and deep retinal capillary layer.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    7 Years to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. 7~17 years old;

    2. Spherical equivalent refraction (SER) -1.00 to -5.00D;

    3. Astigmatism≤ 2.50D;

    4. Refractive anisometry (difference between the two equivalent spherical lenses) ≤ 1.50D;

    5. Best corrected visual acuity (BCVA) in either eye ≥ 20/20;

    6. Currently willing to use low-intensity red light treatment;

    7. Be able to understand the purpose of the trial, voluntarily participate and have the subject and his legal guardian sign an informed consent form.

    Exclusion Criteria:
    1. strabismus (apparent strabismus) or amblyopia;

    2. Correction of abnormal vision in either eye;

    3. Any eye disease that may be related to myopia or affect refractive development, such as history of photosensitivity, macular disease, moderate to severe dry eye, corneal disease, cataract, vitreoretinal disease, infectious conjunctivitis, uveitis, opticnerve damage, congenital optic nerve development abnormalities or other eye diseases;

    4. Systemic diseases, such as hypertension, lupus erythematosus, albinism, diabetes, etc;

    5. previous history of convulsions, tics, central nervous system underdevelopment, psoriasis, epilepsy and psychiatric and psychological diseases;

    6. used within 3 months or planned to use low-concentration atropine eye drops during the study;

    7. Those who have previously used orthokeratology lenses, peripheral defocusing glasses, multifocal soft lenses and other optical therapies to control the progression of myopia, and the elution period is less than three months;

    8. Other situations in which the investigator believes that the patient is not suitable to participate in this study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sun Yat-sen University Zhongshan Ophthalmic Center (Zhujiang New Town Campus) Guangzhou China

    Sponsors and Collaborators

    • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Investigators

    • Study Chair: Ma Jin, professor, Professor at Sun Yat-sen University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jin Ma, Professor at Sun Yat-sen University, Chief Physician at Sun Yat-sen University Hospital, and Doctoral Supervisor at Sun Yat-sen University., Zhongshan Ophthalmic Center, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT06034912
    Other Study ID Numbers:
    • RLRL RCT
    First Posted:
    Sep 13, 2023
    Last Update Posted:
    Sep 13, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 13, 2023